Gain Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotech company focused on allosteric small molecule therapies, announced its CEO Gene Mack's participation in two upcoming investor conferences. Mack will engage in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference on June 17 at 7:00 a.m. EST, and deliver a corporate presentation at BIO 2025 on June 18 at 1:45 p.m. EST at the Boston Convention Center. Investors can request one-on-one meetings through conference representatives or contact the company directly at ir@gaintherapeutics.com.

BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences:

• H.C. Wainwright 6^th Annual Neuro Perspectives Hybrid Conference
  • Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D.
• BIO 2025
  • Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition Center.

Registered attendees can request one-on-one meetings with Gain management via your H.C. Wainwright banking representative or the BIO conference scheduling platform, respectively.

If you are unable to attend the conferences and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investors:
Gain Therapeutics, Inc. 
Apaar Jammu 
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com

LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com

Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

FAQ

When is Gain Therapeutics (GANX) presenting at the H.C. Wainwright Neuro Conference 2025?

Gain Therapeutics CEO Gene Mack will participate in a virtual fireside chat at the H.C. Wainwright Neuro Conference on Tuesday, June 17, 2025, at 7:00 a.m. EST.

What time is Gain Therapeutics (GANX) presenting at BIO 2025?

Gain Therapeutics CEO Gene Mack will give a corporate presentation at BIO 2025 on Wednesday, June 18, 2025, at 1:45 p.m. EST in Room 153C at the Boston Convention and Exhibition Center.

How can investors schedule meetings with Gain Therapeutics (GANX) management?

Investors can request meetings through H.C. Wainwright banking representatives, the BIO conference scheduling platform, or by emailing ir@gaintherapeutics.com.

What type of company is Gain Therapeutics (GANX)?

Gain Therapeutics is a clinical-stage biotechnology company that specializes in developing next-generation allosteric small molecule therapies.